Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ViroGates ASOCSE:VIRO 54 5-Year Yield-on-Cost % is 0.00 as of Jul. 27, 2026. GuruFocus rates OCSE:VIRO with a GF Score™ of 54/100 and a GF Value™ of kr6.68 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 323 Medical Devices & Instruments companies, ViroGates AS ranks worse than 309597.21% on this metric.
ViroGates AS's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for ViroGates AS's 5-Year Yield-on-Cost % or its related term are showing as below:
OCSE:VIRO's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.51 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ViroGates AS (OCSE:VIRO) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
ViroGates AS 5-Year Yield-on-Cost % Related Terms
OCSE:VIRO vs ABT, SYK, MDT: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, ViroGates AS's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ViroGates AS 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ViroGates AS's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where ViroGates AS's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of ViroGates AS is calculated as
ViroGates AS (OCSE:VIRO) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 27, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on ViroGates AS and its competitors. According to the industry distribution chart, ViroGates AS ranks #999999 out of 323 companies in the Medical Devices & Instruments industry.
Is ViroGates AS's 5-Year Yield-on-Cost % too high?
ViroGates AS's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, ViroGates AS ranks #999999 out of 323 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, ViroGates AS has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ViroGates AS's 5-Year Yield-on-Cost % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ViroGates AS ranks #999999 out of 323 companies for 5-Year Yield-on-Cost %. This places ViroGates AS in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.51, based on 323 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on ViroGates AS and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ViroGates AS's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ViroGates AS stock overvalued right now?
Based on GuruFocus' analysis, ViroGates AS (OCSE:VIRO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr6.68, compared to a current price of kr9.55 — trading 43% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. ViroGates AS's overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For ViroGates AS (OCSE:VIRO), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ViroGates AS (OCSE:VIRO) Overvalued in 2026?
Based on GuruFocus' analysis, ViroGates AS stock appears to be overvalued.
The current stock price of kr9.55 is trading 43% above its estimated GF Value™ of kr6.68.
GuruFocus considers ViroGates AS to be Significantly Overvalued.
Key valuation signals for OCSE:VIRO:
5-Year Yield-on-Cost %: 0.00
GF Value™: kr6.68 vs. price of kr9.55 (43% above fair value)
No single metric tells the full story. See the OCSE:VIRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ViroGates AS is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and hospitals. The company markets its blood test products under the suPARnostic brand. Its product portfolio comprises suPARnostic TurbiLatex, suPARnostic Quick Triage, and suPARnostic Auto Flex ELISA kit. These products are mainly used to measure the suPAR (soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream.
54GF Score
Get the complete analysis for OCSE:VIRO
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:VIRO has been successfully added to your 
